Skip to main content

Advertisement

Table 3 Impact of clinicopathological parameters, including performance status and LINE-1 methylation status, on cancer recurrence in stage III or high-risk stage II CRCs (n = 336), assessed by univariate and multivariate Cox regression analyses

From: Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients

Parameters Univariate analysis Multivariate analysis
HR 95 % C.I. P a HR 95 % C.I. P a
Gender (male vs. female) 1.66 0.834–3.321 0.149    
Age (≥60 years vs. <60 years) 1.45 0.774–2.719 0.245    
BMI (overweight vs. normal) 1.29 0.674–2.454 0.445    
Tumor location (distal vs. proximal) 1.94 0.897–4.205 0.092    
Pathology (mucinous vs. non-mucinous) 1.29 0.311–5.343 0.726    
Differentiation (high grade vs. low grade) 1.15 0.353–3.718 0.821    
T stage (T4 vs. T1, 2, 3) 2.41 1.179–4.908 0.016 2.33 1.142–4.761 0.020
N stage (N 2 vs. N0, 1) 2.51 1.355–4.654 0.003 2.46 1.328–4.569 0.004
Microsatellite status (MSI-H vs. MSS + MSI-L) 1.24 0.381–4.002 0.725    
Performance status (PS ≥ 1 vs. PS = 0) 1.46 0.766–2.770 0.251    
LINE-1 methylation (low vs. high) 2.15 0.984–4.701 0.055    
  1. BMI body mass index, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, PS performance status
  2. aCox proportional hazard regression model, adjusted for other selected covariates